Recruitment

Recruitment Status
Active, not recruiting
Estimated Enrollment
1000

Summary

Conditions
  • Advanced Cancer
  • Metastatic Cancer
Type
Interventional
Phase
Not Applicable
Design
Allocation: RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Health Services Research

Participation Requirements

Age
Between 21 years and 125 years
Gender
Both males and females

Description

This is a cluster RCT at up to 50 sites where randomization will occur in a 1:1 ratio at the site level (not at the individual patient level). Therefore, up to 25 sites will be randomized to the PRO-TECT intervention arm (patient-reporting of symptoms plus access to standardized symptom management g...

This is a cluster RCT at up to 50 sites where randomization will occur in a 1:1 ratio at the site level (not at the individual patient level). Therefore, up to 25 sites will be randomized to the PRO-TECT intervention arm (patient-reporting of symptoms plus access to standardized symptom management guideline), and up to 25 sites will be randomized to the control arm (usual care delivery plus access to standardized symptom management guideline). Specifically: PROCEDURES AT ALL SITES (CONTROL SITES AND INTERVENTION SITES): Site staff (CRA and Nurse Champion required) will attend the site initiation webinar with UNC staff, including training for the PRO-Core online data management system and orientation to the symptom management guidelines. At enrollment, all participants will be given a booklet with patient-level symptom advice and a link to the content online. All participants will receive compensation for participation, mailed to them as gift cards by UNC. CRAs will train all participants how to complete outcomes questionnaires for the trial using the PRO-Core online system. Participants will be given a choice to complete these in clinic or from home online, or if necessary via paper in clinic (with the CRA entering the data into PRO-Core). If the patient does not self-complete this information, the CRA will contact them to collect the information and then enter it into PRO-Core. The outcomes questionnaires will be completed at baseline; and at month 1 (+/- 2 weeks); and at months 3, 6, 9, and 12/off-study (+/- 4 weeks each), and will be available in English, Spanish, or Mandarin Chinese. At each time point, the CRA will contact the participant to remind them about the upcoming questionnaire and offer help. Chart abstraction will be conducted by CRAs at baseline and at off-study for each participant, with data entered into the PRO-Core system. Date of death information will additionally be abstracted at 18 and 24 months, and possibly later per the UNC study team. CRAs will be asked to complete a feedback survey (entered by the CRA into the PRO-Core online system) and may be asked to participate in a brief telephone debriefing and/or site visit. Accrual will be monitored in a weekly teleconference between the UNC team and site CRAs. ADDITIONAL PROCEDURES AT INTERVENTION SITES ONLY: At baseline, CRAs will also train patients to self-report symptoms and physical functioning using the PRO-Core system weekly for up to a year, with a choice to do this online or via an automated telephone system (patient choice), and a choice of English, Spanish, or Mandarin Chinese. Whenever a concerning symptom is reported, an automated "email alert" notification will be sent to the site CRA. The CRA will forward the email alert to the responsible clinical nurse (or other covering clinician) and CC the site's Nurse Champion. Within 72 hours, the CRA will document what action(s), if any, were taken by the nurse in response to the alert (entered by the CRA into a form in the PRO-Core system). A symptom report will be printed/generated by the site CRA whenever the patient has a clinic visit, and will be given to the oncologist and nurse caring for the patient.

Tracking Information

NCT #
NCT03249090
Collaborators
  • Patient-Centered Outcomes Research Institute
  • University of North Carolina
  • Mayo Clinic
  • American Society of Clinical Oncology
  • American Cancer Society, Inc.
  • Dana-Farber Cancer Institute
Investigators
Study Chair: Ethan Basch, MD University of North Carolina, Chapel Hill